{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:19:36Z","timestamp":1785766776351,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biogen Japan Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12325-018-0788-8","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T19:44:01Z","timestamp":1536695041000},"page":"1598-1611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension"],"prefix":"10.1007","volume":"35","author":[{"given":"Hirofumi","family":"Ochi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Niino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"issue":"9648","key":"788_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"key":"788_CR2","unstructured":"Multiple Sclerosis International Federation. Atlas of MS 2013: mapping multiple sclerosis around the World. http:\/\/www.msif.org\/wp-content\/uploads\/2014\/09\/Atlas-of-MS.pdf. Accessed 17 Apr 18."},{"issue":"3","key":"788_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/WCO.0000000000000328","volume":"29","author":"H Ochi","year":"2016","unstructured":"Ochi H, Fujihara K. Demyelinating diseases in Asia. Curr Opin Neurol. 2016;29(3):222\u20138.","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"788_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/WCO.0000000000000315","volume":"29","author":"SH Kim","year":"2016","unstructured":"Kim SH, Kim HJ. Central nervous system neuroinflammatory disorders in Asian\/Pacific regions. Curr Opin Neurol. 2016;29(3):372\u201380.","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"788_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2040622316653307","volume":"7","author":"RA Linker","year":"2016","unstructured":"Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther Adv Chronic Dis. 2016;7(4):198\u2013207.","journal-title":"Ther Adv Chronic Dis"},{"issue":"9","key":"788_CR6","first-page":"883","volume":"54","author":"Y Onizuka","year":"2017","unstructured":"Onizuka Y, Hiramatsu K, Hase M, et al. Review of dimethyl fumarate (Tecfidera\u00ae) Part 2: safety in patients with multiple sclerosis. [in Japanese]. Med Consult New Remedies. 2017;54(9):883\u201394.","journal-title":"Med Consult New Remedies"},{"key":"788_CR7","unstructured":"AdisInsight. Dimethyl fumarate\u2014Biogen [last updated 12 January 2018]. http:\/\/adisinsight.springer.com\/drugs\/800019706. Accessed 23 Jan 2018."},{"issue":"12","key":"788_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"issue":"12","key":"788_CR9","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"2","key":"788_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1352458516649037","volume":"23","author":"R Gold","year":"2017","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253\u201365.","journal-title":"Mult Scler"},{"issue":"3_suppl","key":"788_CR11","first-page":"P607","volume":"22","author":"T Saida","year":"2016","unstructured":"Saida T, Yamamura T, Kondo T, et al. Placebo-controlled phase 3 study of delayed-release dimethyl fumarate in patients with relapsing multiple sclerosis from Asia-Pacific and other countries. Mult Scler J. 2016;22(3_suppl):P607.","journal-title":"Mult Scler J"},{"issue":"16 Suppl","key":"788_CR12","first-page":"363","volume":"88","author":"T Saida","year":"2017","unstructured":"Saida T, Yamamura T, Kondo T, et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries: interim analysis of the APEX extension study. Neurology. 2017;88(16 Suppl):363.","journal-title":"Neurology"},{"issue":"6","key":"788_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald criteria\u201d. Ann Neurol. 2005;58(6):840\u20136.","journal-title":"Ann Neurol"},{"issue":"4","key":"788_CR14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907\u201311.","journal-title":"Neurology"},{"issue":"2","key":"788_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/acn3.148","volume":"2","author":"V Viglietta","year":"2015","unstructured":"Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2(2):103\u201318.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"788_CR16","doi-asserted-by":"publisher","first-page":"1582 e9","DOI":"10.1016\/j.clinthera.2013.08.009","volume":"35","author":"SI Sheikh","year":"2013","unstructured":"Sheikh SI, Nestorov I, Russell H, et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013;35(10):1582 e9\u20131594 e9.","journal-title":"Clin Ther"},{"issue":"3","key":"788_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","volume":"6","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6(3):220\u20139.","journal-title":"Neurol Clin Pract"},{"key":"788_CR18","unstructured":"Biogen. TECFIDERA\u00ae(dimethyl fumarate) delayed-release capsules, for oral use. Highlights of prescribing information. https:\/\/www.tecfidera.com\/content\/dam\/commercial\/multiple-sclerosis\/tecfidera\/pat\/en_us\/pdf\/full-prescribing-info.pdf. Accessed 17 Apr 18."},{"issue":"2","key":"788_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40120-015-0037-x","volume":"4","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Erwin AA, Agrella S, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a Delphi study. Neurol Ther. 2015;4(2):137\u201346.","journal-title":"Neurol Ther"},{"issue":"1_suppl","key":"788_CR20","first-page":"P305","volume":"20","author":"M M\u00e4urer","year":"2014","unstructured":"M\u00e4urer M, Voltz R, Begus-Nahrmann Y, et al. Adherence project with German MS-patients: can an approach of individualized patient counseling improve adherence? Mult Scler J. 2014;20(1_suppl):P305.","journal-title":"Mult Scler J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0788-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:33:15Z","timestamp":1724412795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0788-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0788-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"21 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}